Prevalence of a particularly dangerous form of methicillin resistant Staphylococcus aureus (MRSA) jumped three-fold in just two years, in hospitals in the United Kingdom, according to a paper in the October 2012 issue of the Journal of Clinical Microbiology.
This particular pathogen emerged in the U.S. in 1998, and "is endemic within many US hospitals," an observation which led to the current study being conducted, says coauthor Gopal Rao of Northwick Park Hospital, Harrow, Middlesex, UK.
The MRSA in question contains a toxin called Panton-Valentine leukocidin (PVL), which destroys leukocytes (a type of white blood cell), kills skin and mucus membranes, and confers increased virulence. In some cases, they cause invasive disease, most notably necrotizing hemorrhagic pneumonia, which has a high mortality rate.
The United Kingdom's Health Protection Agency first reported that PVL-methicillin resistant S. aureus (PVL-MRSA) was an emerging disease in UK in 2005. While most of the MRSA gets transmitted from one person to another within the hospital, most patients infected with MRSA containing the PVL toxin genes acquired it outside of the hospital ("community acquired" MRSA). The Department of Health in UK mandated screening for MRSA in 2008.
Rao and collaborators set out to find out how many patients entering the hospital carried community-acquired MRSA, especially that containing the dangerous PVL genes. During the study period, cases of community-acquired PVL-MRSA jumped threefold, from 0.07 percent to 0.22 percent, while the numbers of patients with hospital-acquired MRSA dropped from 4.6 percent to 2.8 percent. One particular clone of PVL-MRSA, which also carries resistance to clindamycin and tetracycline is particularly worrisome, the researchers note.
Most of the patients carrying PVL-containing strains are males. The study included 56,000 patients.
Reference: Pantelides NM, et al. Preadmission screening of adults highlights previously unrecognized carriage of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus in London: a cause for concern? J. Clin. Microbiol. 50:3168-3171. 2012.
Â
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.